The CTP-543 THRIVE clinical trials program is designed to evaluate the hair regrowth potential and safety in people with alopecia areata who currently have at least 50% scalp hair loss.
The THRIVE clinical trials program is ongoing with three different research studies exploring the investigational oral drug CTP-543 for the potential treatment of moderate-to-severe alopecia areata.
The THRIVE clinical trials program is now enrolling adults between the ages of 18 to 65 who have been diagnosed with alopecia areata and have a current episode of at least 50% scalp hair loss for at least 6 months and not exceeding 10 years. Note that you can be diagnosed with alopecia areata more than 10 years ago to qualify.
To learn about participating or to see if there is a clinical research study location near you, scroll down or click on the page links.
To see if you may be able to participate, please complete our pre-qualifying questionnaire.
Eligible participants between the ages of 18 to 65 with a current episode of at least 50% scalp hair loss that has lasted at least 6 months but not exceeding 10 years due to alopecia areata. Note that you can be diagnosed with alopecia areata more than 10 years ago to qualify.
These questions are directed to the person who will participate in the clinical research study if they qualify, so "you" as used in the pre-qualifying questionnaire refers to that person.
No. You may take the pre-qualifying questionnaire just to see if you might pre-qualify. Also, participation in a clinical research study is completely voluntary at every step in the process.
Why is the THRIVE Clinical Trials Program Important?
Alopecia areata is an autoimmune disorder. When a person has an autoimmune disorder, their immune system mistakenly attacks a part of their body. In particular, when a person has alopecia areata, cells in the immune system surround and attack hair follicles (the part of your body that makes hair). This attack on the hair follicles causes unpredictable hair loss, typically in patches, but may cause complete hair loss on the scalp and/or body. Patchy hair loss affecting the scalp is a common type.
It is important to understand the different types of alopecia, because the CTP-543 THRIVE clinical trials program is focused on treating alopecia areata specifically. Alopecia areata is different from other types of hair loss, such as male or female pattern baldness. Male or female pattern hair loss, also known as androgenic alopecia, usually occurs gradually and in predictable patterns. These patterns include a receding hairline and bald spots in men and thinning hair along the crown of the scalp in women.
Nearly 2% of the general population will be affected by alopecia areata at some point in their lifetimes.
There is currently no approved medication that treats the cause of hair loss from alopecia areata. The investigational oral drug, CTP-543, is intended to treat the underlying autoimmune process that results in hair loss from alopecia areata.
Before new medications can be approved for public use, they must be tested in clinical research studies like those in the THRIVE clinical trials program. The THRIVE clinical trials program will look at the safety and effectiveness of the investigational oral drug, CTP-543, on hair loss associated with alopecia areata.
Although there are many definitions, a clinical research study is generally considered to be health-related clinical research in people with a specific condition using a pre-defined written protocol.
Click here to learn more about clinical research.